The Epidemiology of Chickenpox in England, 2016-2022: An Observational Study Using General Practitioner Consultations.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
27 Oct 2023
Historique:
received: 26 09 2023
revised: 24 10 2023
accepted: 25 10 2023
medline: 27 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Chickenpox is a common childhood disease caused by varicella-zoster virus (VZV). VZV vaccination is not part of the UK childhood immunisation programme, but its potential inclusion is regularly assessed. It is therefore important to understand the ongoing burden of VZV in the community to inform vaccine policy decisions. General practitioner (GP) chickenpox consultations were studied from 1 September 2016 to 9 December 2022. Over the study period, the mean weekly chickenpox consultation rate per 100,000 population in England was 3.4, with a regular peak occurring between weeks 13 and 15. Overall, rates decreased over time, from a mean weekly rate of 5.5 in 2017 to 4.2 in 2019. The highest mean weekly rates were among children aged 1-4 years. There was no typical epidemic peak during the COVID-19 pandemic, but in 2022, rates were proportionally higher among children aged < 1 year old compared to pre-pandemic years. Chickenpox GP consultation rates decreased in England, continuing a longer-term decline in the community. The COVID-19 pandemic impacted rates, likely caused by the introduction of non-pharmaceutical interventions to prevent SARS-CoV-2 transmission. The lasting impact of the interruption of typical disease transmission remains to be seen, but it is important to monitor the chickenpox burden to inform decisions on vaccine programmes.

Identifiants

pubmed: 38005841
pii: v15112163
doi: 10.3390/v15112163
pmc: PMC10674747
pii:
doi:

Substances chimiques

Chickenpox Vaccine 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Yearb Med Inform. 2021 Aug;30(1):44-55
pubmed: 33882603
Clin Infect Dis. 2021 Dec 6;73(11):e3617-e3626
pubmed: 33173938
J Infect. 2016 Sep;73(3):241-53
pubmed: 27283754
Lancet Infect Dis. 2023 Jan;23(1):56-66
pubmed: 36063828
BMC Infect Dis. 2016 Nov 10;16(1):666
pubmed: 27832745
Emerg Med J. 2020 Oct;37(10):600-604
pubmed: 32948621
Br J Gen Pract. 2021 Feb 25;71(704):e166-e177
pubmed: 33558332
Euro Surveill. 2021 Mar;26(11):
pubmed: 33739255
Lancet. 2011 Nov 26;378(9806):1833-4
pubmed: 22118433
JMIR Public Health Surveill. 2022 Dec 19;8(12):e39141
pubmed: 36534462
BMC Public Health. 2021 Nov 5;21(1):2019
pubmed: 34740346
Euro Surveill. 2019 Oct;24(42):
pubmed: 31640840
BMJ. 2021 Mar 24;372:n819
pubmed: 33762256
Wkly Epidemiol Rec. 2014 Jun 20;89(25):265-87
pubmed: 24983077
Arch Dis Child. 2016 Jan;101(1):2-3
pubmed: 26342095
Commun Dis Public Health. 2000 Sep;3(3):213-5
pubmed: 11014039
Clin Exp Pediatr. 2022 Dec;65(12):555-562
pubmed: 36457198
BMC Public Health. 2022 Dec 12;22(1):2318
pubmed: 36510205
Clin Infect Dis. 2021 Jun 15;72(12):2199-2202
pubmed: 32986804
Epidemiol Infect. 2017 Oct;145(13):2678-2682
pubmed: 28853391
Br J Gen Pract. 2006 Nov;56(532):820-4
pubmed: 17132347

Auteurs

Megan Bardsley (M)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Paul Loveridge (P)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Natalia G Bednarska (NG)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Sue Smith (S)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Roger A Morbey (RA)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Gayatri Amirthalingam (G)

Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London NW9 5EQ, UK.

William H Elson (WH)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6ED, UK.

Chris Bates (C)

TPP SystmOne, Leeds LS18 5PX, UK.

Simon de Lusignan (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6ED, UK.

Daniel Todkill (D)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Alex J Elliot (AJ)

Real-Time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham B2 4BH, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH